Healthcare

Cochlear reported sales revenue of A$2.3 billion, up 2% in constant currency and up 6% in the second half, and underlying net profit of A$322 million, at the upper end of revised guidance. The company said cochlear implant revenue was flat and grossMarginlower, with …

CSL entered an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. The drug is in an ongoing Phase 2 trial in ANCA-associated vasculitis and rapidly progressive glomerulonephritis. CSL will make an initial …

The company reported a cash position of A$152.9 million at 30 September 2026. The cohort expansion of the Phase I/IIa SECuRE trial, evaluating 67Cu-SAR-bisPSMA with enzalutamide, achieved its recruitment target in October 2026, and topline data are anticipated. The company said the CLARIFY pivotal …

Clinuvel said it filed a dossier forMarketingauthorisation of NEURACTHEL Instant, a branded generic formulation of tetracosactide, its second pharmaceutical product, with national European regulators through the decentralised procedure. If approved, the company will be able to commercialise the product in the European Union. The …

EBOS reported revenue growth of 9.9% to $13.5 billion and underlying EBITDA growth of 5.0% to $614 million. Growth was broad-based across Healthcare and Animal Care, with contributions from recent acquisitions, despite elevated fuel costs and foreign exchange headwinds. All FY26 guidance metrics were …

Fisher & Paykel said its first-half guidance, to 30 September 2026, assumed revenue of about NZ$1.24 billion and net profit after tax of about NZ$280 million at 31 July exchange rates. Chief executive Lewis Gradon attributed the strong start to continuedDemandfor the latest hardware …

Healius agreed to sell Agilex Biolabs to Novotech for an enterprise value of A$160 million. Completion is expected during the second half of FY27, subject to satisfaction of certain conditions.